Compare CPRI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPRI | MLYS |
|---|---|---|
| Founded | 1981 | 2019 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.1B |
| IPO Year | 2011 | 2023 |
| Metric | CPRI | MLYS |
|---|---|---|
| Price | $26.02 | $36.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | $26.36 | ★ $46.40 |
| AVG Volume (30 Days) | ★ 2.7M | 1.6M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,369,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.86 | $8.24 |
| 52 Week High | $28.27 | $47.65 |
| Indicator | CPRI | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 61.14 | 40.09 |
| Support Level | $25.64 | $35.77 |
| Resistance Level | $28.27 | $44.13 |
| Average True Range (ATR) | 0.95 | 1.93 |
| MACD | 0.00 | -0.64 |
| Stochastic Oscillator | 53.04 | 14.95 |
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. Capri also owns a third brand, Versace, but has agreed to sell it to Prada. John Idol has served as Capri's CEO since 2003.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.